Drug search by name

Nabumetone and Liver disease

Result of checking the interaction of drug Nabumetone and disease Liver disease for safety when used together.

Check result:

Nabumetone <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The biotransformation of nabumetone to its active metabolite (6-methoxy-2-naphthylacetic acid, or 6MNA) and the further metabolism of 6MNA to inactive substances are dependent upon hepatic function and could be reduced in patients with severe hepatic impairment. The protein binding of 6MNA may also be altered in liver disease. Clinical data concerning the potential consequences of these effects are limited.

References:

Hyneck ML "An overview of the clinical pharmacokinetics of nabumetone." J Rheumatol 19 (1992): 20-4
Maleev A, Vlahov V, Gruev I, Dierdorf D, Kostova N, Bacracheva N "Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone." Int J Clin Pharmacol Ther Toxicol 24 (1986): 425-9
Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR "Metabolism of nabumetone (BRL 14777) by various species including man." Xenobiotica 14 (1984): 327-37
"Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
Brett MA, Buscher G, Ellrich E, et al. "Lack of enterohapatic circulation of the active metabolite of nabumetone in humans." J Rheumatol 19 (1992): 81-2

Nabumetone

Generic Name: nabumetone

Brand Name: Relafen, Relafen DS

Synonyms: n.a.

What is Nabumetone?